The Delaware Court of Chancery has approved a settlement in the derivative lawsuit against The Beauty Health Company, a publicly traded skincare company. The case, known as In re The Beauty Health Company Consolidated Stockholder Litigation (C.A. No. 2024-0114-LWW), involved claims related to the company's HydraFacial Syndeo skincare treatment system. The settlement aims to address management oversight issues and improve product quality oversight.
The lawsuit was filed by stockholders Margie Elstein and Richard Montague, who alleged that the company's board of directors failed to adequately manage problems with the HydraFacial Syndeo device, which had significant hardware and software defects. This litigation is particularly important as it highlights corporate governance issues and the responsibilities of directors to ensure product quality and transparency in communications with investors.
Background
The Beauty Health Company, known for its HydraFacial skincare treatments, launched the HydraFacial Syndeo Delivery System in March 2022. This device was expected to enhance the customer experience but instead faced numerous issues, leading to customer dissatisfaction and significant financial losses. By late 2023, the company announced that it would replace all first- and second-generation Syndeo devices, incurring over $63 million in write-downs and remediation expenses. Following this announcement, the company's stock price plummeted from $13.90 to approximately $1.45 per share, prompting federal securities litigation.
Elstein and Montague initiated the derivative lawsuit after conducting investigations under Delaware law, claiming that the board of directors breached their fiduciary duties by failing to disclose the product's defects and misrepresenting the company's financial health. The plaintiffs alleged that the directors either knowingly allowed false information to be disseminated or ignored significant red flags regarding the product's performance.
The Ruling
On August 11, 2026, Vice Chancellor Lori W. Will ruled on the settlement agreement reached by the parties. The court approved the settlement, stating, "Because the settlement releases weak claims in exchange for minor enhancements, the consideration is adequate and I approve it." The settlement includes several therapeutic benefits aimed at improving oversight of product quality, such as formalizing existing management committees and designating a quality ombudsperson.
However, the court also awarded a significantly reduced attorneys' fee of $100,000, reflecting the minimal corporate benefit achieved through the settlement. The ruling emphasized that the released claims were weak and that the improvements offered by the settlement were largely formalizations of existing practices.
Impact
The approval of this settlement is significant as it underscores the responsibilities of corporate directors to manage product quality and disclose pertinent information to shareholders. While the settlement provides some enhancements to the company's governance structure, it also highlights the challenges plaintiffs face in derivative lawsuits, particularly when the claims are perceived as weak. The court's ruling sets a precedent for how similar cases may be evaluated in the future, particularly regarding the adequacy of settlements in derivative actions.
Going forward, this case may influence how companies approach product quality oversight and the importance of transparent communication with investors. The ruling may also serve as a cautionary tale for directors about the potential consequences of failing to address known issues within their companies.
What's Next
While the settlement has been approved, the plaintiffs' counsel may still pursue further legal action in related federal securities litigation. The court's decision in this case may also prompt other shareholders to consider similar derivative actions if they believe their companies are failing to uphold their fiduciary duties.